SHANGHAI, Oct. 26, 2020 /PRNewswire/ -- Reistone Biopharma Co. Ltd. ("Reistone"), an innovative clinical stage biopharmaceutical company focused on developing novel medicines for immuno-inflammatory diseases with high unmet medical needs, today announced

Recently, Reistone Biopharma Company Limited received the Notice of Clinical Trial approved and issued by NMPA, and was approved to carry out the clinical trial of SHR0302 base ointment to be intended for vitiligo.

Shanghai, China, July 31, 2020 / -- Reistone Biopharma Company Limited (“Reistone Biopharma”) today announced that, the first and second patients in China were enrolled and dosed in Dermatology Hospital of Southern Medical University in the phase II clini